|
Synonyms: ION 1166998 | ION-1166998 | ION373 | Zanvastro®
zilganersen is an approved drug
Compound class:
Nucleic acid
Comment: Zilganersen (ION373) is an 20-mer gapmer antisense oligonucleotide (ASO) that is designed to reduce synthesis of glial fibrillary acidic protein (GFAP) in the brain of patients with Alexander disease.
Chemically it has a phosphorothioate/phosphate backbone, modified 2'-O-methoxyethyl ribose and deoxyribose sugars and base substitutions. Full sequence is: all-P-ambo-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)adenylyl-(3'→5')-2'-O-(2-methoxyethyl)guanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'→5')-2'-O-(2-methoxyethyl)adenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-O-(2-methoxyethyl)adenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidine |
| No information available. |
Summary of Clinical Use ![]() |
| Zilganersen (Zanvastro®) was approved by the US FDA in September 2026, to treat paediatric and adult Alexander disease. It had previously received FDA orphan drug (in 2020) [1] and rare pediatric disease designations for this indication. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04849741 | A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD) | Phase 3 Interventional | Ionis Pharmaceuticals, Inc. | ||